Please ensure Javascript is enabled for purposes of website accessibility

Could Coronavirus Variants Boost Pfizer's Vaccine Sales By 50%?

By Keith Speights - Mar 2, 2021 at 5:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Probably not in the way some might think.

Fifteen billion dollars: That's how much Pfizer (PFE -0.23%) projected last month in its Q4 update that it will make this year from its COVID-19 vaccine, BNT162b2. Sure, the company splits profits equally with its partner, BioNTech (BNTX 5.63%), but we're still talking about a lot of money.

The actual amount will almost surely be even higher. Since Pfizer's update, the U.S. government has ordered another 100 million doses of BNT162b2. But could Pfizer's revenue from the vaccine be 50% higher because of another factor -- new "variants of concern" of SARS-CoV-2, the coronavirus that causes COVID-19?

Vaccine vial with a dollar sign inside it, next to a syringe and another toppled vial labeled SARS-CoV-2 Vaccine

Image source: Getty Images.

Good things come in threes

Pfizer and BioNTech announced last week that they've begun a study to evaluate a third dose of BNT162b2. Why add another dose to the two-dose regimen that has already demonstrated an efficacy of 95%? Blame it on the new coronavirus variants.

The companies want to see whether an additional booster shot will provide greater immunity against new variants. Individuals who participated in the phase 1 clinical study of BNT162b2 conducted in the U.S. will be given an opportunity to receive a booster shot of the current version of the vaccine six to 12 months after their second dose.

The B.1.351 variant first identified in South Africa is one of the biggest worries among global healthcare leaders. Pfizer and BioNTech are talking with the U.S. Food and Drug Administration (FDA), and regulatory authorities in other countries, about another pivotal study to evaluate a version of BNT162b2 that specifically targets this variant.

Pfizer CEO Albert Bourla tried to alleviate concerns about the efficacy of the two-dose regimen of BNT162b2 that's already being given to millions of people. He said that "we have not seen any evidence that the circulating variants result in a loss of protection provided by our vaccine." BioNTech CEO Ugur Sahin referred to the two companies' moves as part of a proactive strategy being undertaken so that Pfizer and BioNTech will "be prepared for different scenarios."

A 50% jump in revenue?

Let's return to that $15 billion sales projection for BNT162b2. Pfizer arrived at that number based on a two-dose regimen of the vaccine. If a third dose is ultimately required, could Pfizer's revenue jump 50%? The math might seem sound. However, the underlying assumptions could prove to be shaky.

There are simply too many unknowns at this point. It remains to be seen if the B.1.351 variant will become widespread enough in the U.S. and other countries to overcome immunity from existing vaccines. Even if that happens, two doses of BNT162b2 could be effective enough that a booster dose isn't required.

It's also quite possible that a third dose of Pfizer and BioNTech's vaccine won't help very much in increasing efficacy against the new variants. We don't even know yet how often booster shots will be needed for vaccines designed to fight the original strain of SARS-CoV-2, never mind the new variants.

Perhaps most importantly, Pfizer stated that it's looking at developing a version of BNT162b2 that's variant-specific. By the time governments see the need for more effective vaccines for new variants, the company could have a new two-dose (or perhaps even single-dose) vaccine specifically designed for them.

Could Pfizer's revenue be higher if a third dose of BNT162b2 proves to significantly increase efficacy against B.1.351 and other variants? Perhaps. But don't count on a 50% increase.

An important takeaway

One factor could make a real difference in the growth prospects for the big pharma stock, though. More coronavirus variants of concern are almost assuredly on the way. The companies able to rapidly respond to these variants will be in the best positions to dominate the global COVID-19 vaccine market in the future.

I'd argue that Pfizer and BioNTech are well-prepared to target new variants. The companies' quick moves against the current strains show their desire to be proactive. Messenger RNA (mRNA) technology also offers some inherent advantages in rapid development of new vaccine versions. It's no coincidence that the Pfizer-BioNTech partnership and Moderna were first to market in the U.S. with their mRNA COVID-19 vaccines.

New coronavirus variants might not boost Pfizer's fortunes significantly this year. But we could see a much different story over the long run.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.31 (-0.23%) $0.12
BioNTech SE Stock Quote
BioNTech SE
BNTX
$157.50 (5.63%) $8.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.